Biotechnology - Biotechnology, Bayer

Filter

Current filters:

BiotechnologyBayer

Popular Filters

1 to 25 of 59 results

Sustained improvement in vision among two-year results from Phase III Eylea trial

Sustained improvement in vision among two-year results from Phase III Eylea trial

18-07-2014

US-based biotech company Regeneron has said its Phase III trials of Eylea (aflibercept) injection for…

afliberceptBayerBiotechnologyDiabetic retinopathyEyleaLaser coagulationMacular edemaOphthalmicsRegeneronResearchUSA

Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

23-06-2014

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with…

BayerBiotechnologyDimension TheapeuticsHematologyLicensingResearch

Genzyme to resubmit Lemtrada NDA for FDA review

Genzyme to resubmit Lemtrada NDA for FDA review

07-04-2014

Genzyme, the biotech subsidiary of French drug major Sanofi, said this morning that, following “constructive…

BayerBiotechnologyLemtradaNeurologicalNorth AmericaRegulationSanofiUSA

X-Chem licenses drug discovery program to Bayer

X-Chem licenses drug discovery program to Bayer

17-02-2014

X-Chem Inc, a privately held US biotechnology company focused on applying its innovative drug discovery…

BayerBiotechnologyLicensingOncologyX-Chem

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Kemal Malik appointed Bayer board member with responsibility for innovation

Kemal Malik appointed Bayer board member with responsibility for innovation

20-12-2013

The supervisory board of German drugs and chemicals major Bayer (BAYN: DE) has appointed Kemal Malik…

BayerBiotechnologyBoardroomGermanyPharmaceuticalUK

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

06-11-2013

US biotech firm Regeneron Pharmaceuticals has posted financial and operating results for the third quarter…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Nexavar gains FDA priority review for thyroid cancer sNDA

27-08-2013

German drug major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), which has just agreed…

BayerBiotechnologyNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Onyx Pharma accepts increased bid from Amgen

27-08-2013

Amgen (Nasdaq: AMGN), the world largest independent biotech group, said on Sunday (August 25) that the…

AmgenBayerBiotechnologyKyprolisMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizer

Bayer gets Japanese OK for GI stromal tumors drug

20-08-2013

German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…

Asia-PacificBayerBiotechnologyOncologyPharmaceuticalRegulationStivarga

Regeneron revenues leap on Eylea progress

06-08-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares fall 4% to $260 in pre-market…

BayerBiotechnologyEyleaFinancialRegeneron

Eylea meets primary endpoint in Ph III DME study

06-08-2013

German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads

11-07-2013

The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Onyx Pharma rejects Amgen's unsolicited $120 per share takeover offer

01-07-2013

Following a day of speculation and rumor on Friday, US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX)…

AmgenBayerBiotechnologyCelgeneMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizerRoche

Bayer to spend up to $520 million on antibody drug conjugate deal with Seattle Genetics

26-06-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) says it has entered into a new antibody-drug conjugate…

BayerBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

1 to 25 of 59 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top